Table 1 Baseline and disease characteristics by DL
DL1 (n = 3) | DL2 (n = 2) | DL3 (n = 3) | DL4 (n = 6) | Total (n = 14) | |
|---|---|---|---|---|---|
Age (yr), median (range) | 72 (59–74) | 70 (63–76) | 51 (50–53) | 55 (38–61) | 59 (38–76) |
Female gender, n (%) | 1 (33) | 1 (50) | 1 (33) | 1 (17) | 4 (29) |
ECOG, n (%) | |||||
0 | 2 (67) | 1 (50) | 1 (33) | 3 (50) | 7 (50) |
1 | 1 (33) | 1 (50) | 2 (67) | 3 (50) | 7 (50) |
Number of prior therapies, n (%) | |||||
1 | 2 (67) | 1 (50) | 1 (33) | 2 (33) | 6 (43) |
2 | 1 (33) | 1 (50) | 2 (67) | 4 (67) | 8 (57) |
Prior anti-PD(L)1 therapy, n (%) | |||||
Yes | 1 (33) | 0 (0) | 0 (0) | 0 (0) | 1 (7) |
No | 2 (67) | 2 (100) | 3 (100) | 6 (100) | 13 (93) |
Tumor types, n (%) | |||||
MSS-CRC | 0 | 1 (50) | 2 (67) | 4 (67) | 7 (50) |
GEA | 2 (67) | 1 (50) | 1 (33) | 2 (33) | 6 (43) |
NSCLC | 1 (33) | 0 | 0 | 0 | 1 (7) |
